<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643825</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-ONCO 06-004</org_study_id>
    <nct_id>NCT00643825</nct_id>
  </id_info>
  <brief_title>Prolonged Adjuvant Temozolomide vs &quot;Stop &amp; Go&quot; in Glioblastoma Patients</brief_title>
  <acronym>PATSGO</acronym>
  <official_title>Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or &quot;Stop and Go&quot; in Glioblastoma Patients: The PATSGO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay
      relapses in patients with glioblastoma compared to the standard care consisting in
      observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go
      arm).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and adverse event profile of prolonged adjuvant Temozolomide</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>A: prolonged adj TMZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B : Stop and Go</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rechallenging patients with TMZ at relapse</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD</description>
    <arm_group_label>A: prolonged adj TMZ</arm_group_label>
    <other_name>TEMODAR, TEMODAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Observation till Progression then rechallenging with TMZ</description>
    <arm_group_label>B : Stop and Go</arm_group_label>
    <other_name>TEMODAR, TEMODAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed diagnosis of GBM

          2. Availability of pre-treatment GBM tissue to determine the activation status of MGMT
             gene is not mandatory but strongly recommended

          3. Patients must have received radiation and TMZ for 6 weeks followed by 6 months of TMZ.
             Randomization should be performed within the 6 weeks after the last chemotherapy.

          4. A brain MRI with or without a PET-Scan-methionine must be performed before enrolment.

          5. Age ≥ 18 years

          6. Karnofsky Performance status ≥ 60

          7. Normal haematological functions: ANC ≥ 1.5 x 109cells/l, platelets ≥ 100 x 109 cells/l

          8. Normal liver function: total bilirubin &lt; 1.5 x ULN, alkaline phosphatase and
             transaminases (ASAT/ALAT) &lt; 2.5 times the upper limit of the normal range

          9. Serum creatinine &lt; 1.5 x ULN

         10. Clinically normal cardiac function without history of ischemic heart disease in the
             past 12 months. Absence of cardiac insufficiency NYHA grade III and IV, instable
             angina, arrhythmia

         11. No previous or current malignancy (except treated basal or squamous cell skin
             carcinoma, cervix cancer or in situ carcinoma of the breast).

         12. All patients (male and female) with reproductive potential must use effective
             contraception. Females must have a negative serum pregnancy test at entry to study.

         13. Signed informed consent from the patient or legal representative must be obtained.

        Exclusion Criteria:

        All non inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Baurain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Francois BAURAIN, MD, PhD</last_name>
    <phone>+32 2 764 54 71</phone>
    <email>jean-francois.baurain@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <state>Europe</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois BAURAIN, MD, PhD</last_name>
      <phone>+32 2 764 54 71</phone>
      <email>jean-francois.baurain@@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Baurain J-Fr</name_title>
    <organization>Cliniques universitaires Saint-Luc</organization>
  </responsible_party>
  <keyword>Temozolomide</keyword>
  <keyword>Phase II</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Progression-free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

